List of Excipients in Branded Drug UP AND UP MICONAZOLE 7

« Back to Dashboard

Generic Drugs Containing UP AND UP MICONAZOLE 7

Company	Ingredient	NDC	Excipient
Target Corporation	miconazole nitrate	11673-825	BENZOIC ACID
Target Corporation	miconazole nitrate	11673-825	BUTYLATED HYDROXYANISOLE
Target Corporation	miconazole nitrate	11673-825	GLYCERYL MONOSTEARATE
Target Corporation	miconazole nitrate	11673-825	MINERAL OIL

What are the Most Frequently-Used Excipients in UP AND UP MICONAZOLE 7?

# Of NDCs	Excipient
1	BENZOIC ACID
1	BUTYLATED HYDROXYANISOLE
1	GLYCERYL MONOSTEARATE
1	MINERAL OIL

Up & Up Miconazole 7 Excipient Strategy and Commercial Opportunities

Last updated: September 26, 2026

Up & Up Miconazole 7 is an over-the-counter vaginal antifungal containing miconazole nitrate 2% in a seven-day cream regimen. Its commercial position depends less on active-ingredient exclusivity than on formulation performance, consumer convenience, private-label economics, packaging, and compliance with the FDA vaginal antifungal monograph. The product has limited conventional patent protection, leaving excipient optimization and differentiated delivery formats as the primary commercial opportunities.

What is Up & Up Miconazole 7?

Up & Up Miconazole 7 is a store-brand vaginal cream marketed for the treatment of vaginal yeast infections. The product uses miconazole nitrate at a 2% concentration and is applied intravaginally once daily for seven consecutive days.

Attribute	Product position
Brand	Up & Up
Retailer	Target
Active ingredient	Miconazole nitrate
Strength	2%
Dosage form	Vaginal cream
Treatment duration	Seven days
Regulatory category	OTC vaginal antifungal
Primary indication	Treatment of vaginal yeast infections
Likely commercial model	Retailer private label
Reference category	Monistat 7 and equivalent miconazole 2% vaginal creams

Miconazole is an imidazole antifungal that inhibits fungal ergosterol synthesis. The FDA permits miconazole nitrate for OTC vaginal antifungal use under the applicable monograph conditions, including a 2% cream dosage form for a seven-day treatment regimen.[1]

What excipients are used in Up & Up Miconazole 7?

The labeled cream base is designed to disperse miconazole nitrate, provide vaginal coverage, support drug release, and maintain acceptable physical stability. The listed inactive ingredients for comparable miconazole nitrate 2% vaginal cream products include the following:

Excipient	Likely formulation role
Purified water	Continuous aqueous phase
Mineral oil	Emollient and oil-phase vehicle
Stearyl alcohol	Consistency agent and emulsion stabilizer
Glyceryl monostearate	Emulsifier and structure builder
Polysorbate 60	Nonionic surfactant and emulsifier
Hydrogenated vegetable oil	Thickener, emollient, and structure modifier
Benzoic acid	Preservative and pH-control component

The exact Up & Up inactive-ingredient declaration should be verified against the current package label and FDA product record before use in regulatory, litigation, or licensing analysis. Retailer formulations can change while retaining the same active ingredient, strength, route, and treatment regimen.

Why this excipient system is commercially functional

The formulation uses a conventional oil-in-water or structured emulsion approach. Mineral oil and hydrogenated vegetable oil provide lubricity and residence characteristics. Stearyl alcohol and glyceryl monostearate build viscosity and help maintain cream structure. Polysorbate 60 supports emulsification and disperses the lipophilic drug phase. Benzoic acid provides preservation support in the aqueous environment.

This system is commercially attractive because it uses widely available, low-cost excipients with established pharmaceutical and topical-use histories. It is compatible with high-volume contract manufacturing and does not require a novel delivery platform.

How does the seven-day cream compare with other miconazole products?

The principal consumer trade-off is duration versus dose intensity and convenience.

Product type	Typical miconazole strength	Treatment duration	Commercial advantage
Miconazole 7 cream	2%	7 days	Lower daily drug concentration, familiar cream format
Miconazole 3 suppository or cream	Higher daily dose	3 days	Shorter regimen
Miconazole 1	High single dose	1 day	Maximum convenience
Generic vaginal cream	Usually 2%	7 days	Lower price
Clotrimazole vaginal products	Varies	1, 3, or 7 days	Alternative azole brand and generic competition

The seven-day format may be preferred by consumers seeking a longer, lower-intensity regimen. Its disadvantages include repeated application, greater leakage potential, and lower convenience than one-day or three-day products.

Excipient strategy therefore affects competitive performance. A smoother cream with better adhesion and reduced leakage can improve consumer satisfaction without changing the active ingredient or treatment duration.

What excipient improvements could create commercial opportunities?

Reduced leakage and improved residence time

A formulation that remains in place longer could reduce overnight leakage and improve perceived effectiveness. Candidate approaches include:

• Controlled increases in yield stress without excessive stiffness.
• Mucoadhesive polymers at low concentrations.
• Structured lipid phases that resist rapid liquefaction.
• Bioadhesive gels with controlled water uptake.
• Packaging that delivers a consistent, low-volume dose.

The main development constraint is avoiding delayed drug release. A more adhesive system is commercially useful only if it maintains adequate miconazole availability at the site of infection.

Improved cream texture

Consumers commonly evaluate vaginal products on texture, spreadability, residue, and leakage. Excipient optimization can target:

• Lower grittiness.
• Faster spreading.
• Reduced oily residue.
• Lower tackiness.
• More uniform discharge.
• Improved compatibility with applicators.

Polysorbate and fatty-alcohol levels can materially affect viscosity, sensory profile, and emulsion stability. Hydrogenated vegetable oil can provide structure but may increase drag or leave a heavier residue if used at excessive levels.

Lower-irritation preservation strategy

Benzoic acid is a practical preservative, but vaginal products require careful control of pH and preservative concentration. A differentiated product could evaluate alternative preservation systems or lower-preservative formulations, subject to microbial challenge testing and regulatory acceptability.

Potential approaches include:

• Optimized benzoic acid concentration.
• pH adjustment to improve preservative activity.
• Reduced water activity through formulation design.
• Preservative systems with lower irritation potential.
• Single-use packaging that reduces repeated microbial exposure.

The commercial claim should remain limited to substantiated product attributes, such as preservative-free, fragrance-free, or sensitive-skin positioning. Vaginal tolerability claims require clinical or appropriate performance support.

Improved applicator performance

Applicator design is an underused differentiation area. Opportunities include:

• Premeasured single-use applicators.
• Lower-resistance plungers.
• Reduced residual cream in the barrel.
• Tamper-evident individual packaging.
• Applicators made with lower-friction materials.
• Designs that reduce over-insertion risk.

Packaging and delivery components can be protected through design patents, utility patents, trade dress, or supplier exclusivity even when the cream composition itself is difficult to patent.

What patent protection applies to Up & Up Miconazole 7?

Miconazole nitrate is an established active ingredient with no meaningful composition-of-matter exclusivity remaining for a conventional vaginal cream. The seven-day miconazole 2% product is generally exposed to generic and private-label competition.

IP category	Likely position for Up & Up Miconazole 7
Active-ingredient patent	Expired or commercially irrelevant
Conventional cream composition	Limited patent barrier
FDA exclusivity	No meaningful new-drug exclusivity expected
Formulation patent	Possible only for a novel, non-obvious composition
Applicator patent	Potentially available
Packaging patent	Potentially available
Trademark	Up & Up brand protection
Trade secret	Manufacturing parameters and process controls
Retail exclusivity	Possible through private-label supply arrangements

A conventional cream containing miconazole nitrate, mineral oil, water, fatty alcohols, emulsifier, and preservative is unlikely to support a strong blocking patent unless it demonstrates an unexpected technical result. Patentable opportunities are more likely to arise from a specific rheology profile, improved retention, reduced leakage, enhanced stability, or a novel delivery device.

When does Up & Up Miconazole 7 lose exclusivity?

Up & Up Miconazole 7 does not appear to depend on a conventional patent or new-drug exclusivity period. The active ingredient is available through the OTC regulatory framework, and competing products can enter using the same monograph pathway if they satisfy applicable conditions.

The commercially relevant exclusivity is retailer and supplier control rather than statutory exclusivity. Target can differentiate the product through:

• Private-label branding.
• Retail placement.
• Pricing.
• Multipack configuration.
• Digital search prominence.
• Supplier agreements.
• Packaging design.

This structure creates low legal barriers to entry but can create operational barriers. A competing manufacturer must meet FDA quality requirements, establish a reliable supply chain, qualify packaging components, and obtain retail distribution.

What is the FDA regulatory status of miconazole 2% vaginal cream?

Miconazole vaginal antifungal products are regulated as OTC drugs under FDA monograph requirements. The relevant framework includes the vaginal antifungal drug provisions in 21 C.F.R. Part 333.[1]

Key regulatory requirements include:

• Permitted active ingredient and concentration.
• Appropriate dosage form and route.
• Required indications and directions.
• Contraindications and warnings.
• Adequate labeling.
• Current good manufacturing practice compliance.
• Drug product quality and stability.
• Appropriate packaging and applicator controls.

The product is not a biologic and does not face biosimilar competition. Its competitive set consists of branded OTC products, authorized generics, store brands, and alternative vaginal antifungal actives such as clotrimazole and tioconazole.

What formulation patents could protect a future miconazole product?

A future miconazole product could pursue protection around a technically differentiated platform rather than the basic active ingredient.

Candidate patent themes

1. Mucoadhesive vaginal cream
   Claims could cover a defined polymer system, viscosity range, residence time, or drug-release profile.

2. Low-leakage emulsion
   Protection could target a specific oil-to-water ratio, fatty-alcohol system, yield stress, or phase structure.

3. Thermosensitive gel
   A composition that is easy to administer but thickens at vaginal temperature could support composition and method claims.

4. Miconazole suspension with improved uniformity
   Claims could address particle size, crystal form, dispersant system, and dose uniformity.

5. Combination product
   A miconazole formulation combined with a separately justified symptom-relief component could create additional patent and regulatory complexity.

6. Applicator and dose-control system
   A device that limits dose variation or reduces residual product could offer stronger practical differentiation than the cream itself.

Patent strength would depend on claim breadth, prior-art density, reproducible performance data, and whether the formulation delivers an unexpected benefit. Broad claims covering ordinary emulsion ingredients would face substantial obviousness risk.

Which companies compete with Up & Up Miconazole 7?

The main competitive groups are:

• Kenvue, through Monistat-branded miconazole products.
• Private-label retailers, including pharmacy, grocery, and mass-market chains.
• Generic manufacturers, including companies supplying OTC store brands.
• Clotrimazole suppliers, competing through an alternative imidazole.
• Tioconazole suppliers, competing through shorter treatment regimens.

Kenvue’s Monistat franchise has greater brand recognition, while Up & Up competes through price and Target distribution. Store-brand products can capture share when consumers identify the active ingredient and treatment duration but do not require a specific branded product.

What generic launch risks exist?

The primary launch risks are commercial and operational rather than patent-based.

Risk	Impact
Price compression	High
Retailer shelf competition	High
Product leakage complaints	Medium to high
Applicator defects	Medium
Microbial or stability failure	High
Labeling noncompliance	High
Supply interruption	High
Brand switching to one-day products	Medium
Consumer preference for clotrimazole or tioconazole	Medium

A new entrant would have limited ability to charge a premium for the same conventional cream. A premium strategy requires a measurable benefit, such as lower leakage, easier application, improved tolerability, or a materially better applicator.

What licensing opportunities exist for excipients and delivery systems?

Licensing opportunities are more credible in platform technologies than in ordinary excipients. Relevant targets include:

• Mucoadhesive polymers with vaginal-use data.
• Thermogelling systems.
• Low-irritation preservative technologies.
• Pre-filled applicators.
• Single-dose packaging systems.
• Manufacturing processes that improve suspension uniformity.
• Excipients with documented vaginal tolerability.

A licensing deal could combine a private-label retailer, a contract drug manufacturer, and an excipient or device developer. The strongest commercial structure would provide measurable product differentiation while preserving monograph eligibility and avoiding a complex clinical development program.

How strong is the patent estate for Up & Up Miconazole 7?

The patent estate is likely weak for the conventional product and potentially stronger for redesigned delivery systems.

Asset	Estimated strategic strength
Miconazole active ingredient	Low
Conventional seven-day cream	Low
Standard excipient combination	Low
Novel low-leakage formulation	Moderate, if supported by data
Mucoadhesive system	Moderate
Applicator design	Moderate
Packaging configuration	Moderate
Retail brand and trade dress	Moderate within retail channels
Manufacturing process know-how	Moderate as a trade secret

The best defensible position is a layered strategy: maintain monograph compliance, develop a measurable formulation benefit, protect the applicator and packaging, and secure manufacturing know-how through confidential process controls.

Key Takeaways

• Up & Up Miconazole 7 is a miconazole nitrate 2% vaginal cream used for seven days.
• Its conventional excipient system is based on water, mineral oil, fatty alcohols, glyceryl monostearate, polysorbate 60, hydrogenated vegetable oil, and benzoic acid.
• The active ingredient and standard cream format have little meaningful patent exclusivity.
• Commercial differentiation is most feasible through leakage reduction, texture, tolerability, applicator design, and packaging.
• A conventional excipient combination is unlikely to support a strong blocking patent without unexpected performance data.
• The product faces no biosimilar risk; competition comes from branded OTC products, private labels, generics, clotrimazole, and tioconazole.
• The most credible licensing opportunities involve mucoadhesive systems, thermogels, preservative strategies, and delivery devices.
• Retailer control, supply reliability, and consumer experience are more important than patent exclusivity for the current product.

FAQs

Is Up & Up Miconazole 7 the same as Monistat 7?

They use the same general active ingredient and treatment concept, miconazole nitrate 2% administered for seven days. Inactive ingredients, applicators, packaging, and manufacturing sources may differ.

Can a company patent a miconazole 2% vaginal cream?

A basic miconazole 2% cream is unlikely to support meaningful new patent protection. A specific formulation, rheology profile, delivery device, or demonstrated performance improvement may be patentable.

Does miconazole vaginal cream weaken condoms?

Miconazole vaginal creams may reduce the reliability of latex condoms and diaphragms during treatment. Product labeling should be reviewed for the applicable warning and recommended precaution period.[2]

Is a seven-day miconazole product easier to develop than a one-day product?

Usually, a seven-day cream uses a less concentrated daily dose and a conventional formulation platform. A one-day product may require greater attention to drug loading, retention, irritation, and dose uniformity.

What is the best commercial upgrade to Up & Up Miconazole 7?

A low-leakage, low-residue formulation paired with a more precise applicator is the most practical upgrade. It can improve consumer experience without requiring a new active ingredient.

References

1. U.S. Food and Drug Administration. (2024). 21 C.F.R. Part 333: Topical antimicrobial drug products for over-the-counter human use. Electronic Code of Federal Regulations.

2. U.S. Food and Drug Administration. (2024). Miconazole nitrate vaginal cream product labeling. DailyMed.

3. U.S. Food and Drug Administration. (2024). Over-the-counter topical antifungal drug products: Final monograph framework. FDA.

4. U.S. Food and Drug Administration. (2024). Current good manufacturing practice for finished pharmaceuticals, 21 C.F.R. Parts 210 and 211. Electronic Code of Federal Regulations.